Latest Breaking News On - Phase 3 emerald 1 trial nct03778957 - Page 1 : comparemela.com

TACE Plus Durvalumab and Bevacizumab Could Alter SOC in Embolization-Eligible, Unresectable HCC

Riccardo Lencioni, MD, discusses how TACE, durvalumab, and bevacizumab, could represent a new standard of care in embolization-eligible HCC.